Amylyx Pharmaceuticals, Inc. (AMLX)
33.40
-0.35
(-1.04%)
USD |
NASDAQ |
Sep 01, 11:12
Amylyx Pharmaceuticals Cash from Operations (TTM) : -126.58M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -126.58M |
| March 31, 2026 | -120.40M |
| December 31, 2025 | -123.34M |
| September 30, 2025 | -154.45M |
| June 30, 2025 | -165.65M |
| March 31, 2025 | -206.98M |
| December 31, 2024 | -167.65M |
| September 30, 2024 | -95.09M |
| June 30, 2024 | -58.69M |
| March 31, 2024 | 16.50M |
| Date | Value |
|---|---|
| December 31, 2023 | 11.92M |
| September 30, 2023 | -51.33M |
| June 30, 2023 | -89.24M |
| March 31, 2023 | -144.31M |
| December 31, 2022 | -179.87M |
| September 30, 2022 | -158.42M |
| June 30, 2022 | -136.20M |
| March 31, 2022 | -102.79M |
| December 31, 2021 | -74.80M |
| September 30, 2021 | -55.44M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Pfizer Inc. | 13.40B |
| Eli Lilly & Co. | 28.08B |
| Merck & Co., Inc. | 19.97B |
| EyePoint, Inc. | -267.30M |
| Bristol Myers Squibb Co. | 12.78B |